Cantor Fitzgerald Reaffirms “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD)
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a report released on Thursday,Benzinga reports. They presently have a $2.00 price target on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 58.73% from the stock’s current price. LUCD has been […]
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a report released on Thursday,Benzinga reports. They presently have a $2.00 price target on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 58.73% from the stock’s current price. LUCD has been […]
